Search results
Viagra maker Viatris misses revenue estimates on weak demand for older drugs
Reuters via Yahoo Finance· 1 week agoDrugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure ...
This High-Yield Dividend Stock Is a Proven Wealth Creator
Motley Fool· 6 months agoFound in 1849, Pfizer (NYSE: PFE) has transformed the lives of patients and shareholders alike. In...
Want to Collect $1,100 in Dividends? Invest $20,000 in These 2 Stocks
Motley Fool· 1 year agoIf you have $20,000 or more in savings that you can afford to invest in stocks, you may want to...
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
Motley Fool· 2 years agoHere's why they chose Bristol Myers Squibb (NYSE: BMY), Viatris (NASDAQ: VTRS), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (Bristol...
2 Dirt Cheap Dividend Stocks to Buy and Hold
Motley Fool via Yahoo Finance· 2 months agoDividend stocks are great for several reasons. Some use the regular payouts they offer to complement their income, whether in retirement or otherwise,...
Viatris reaffirms 2023 sales forecast on strong demand for newer drugs
Reuters via Yahoo Finance· 1 year ago(Reuters) - Viatris Inc reaffirmed its full-year revenue forecast on Monday and said it was on track to achieve about $500 million in annual sales from its newly launched products, sending its ...
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Motley Fool· 9 months agoViatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic...
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Motley Fool· 9 months agoIf you're looking for a high-yield dividend stock in the healthcare sector, you might be interested...
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Motley Fool via Yahoo Finance· 2 months agoGiven its key role in the fight against COVID-19, the fact that Pfizer (NYSE: PFE) shares are down...
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
Motley Fool· 1 year agoThe long-term thesis for Viatris (NASDAQ: VTRS) rests on its drug pipeline, researching and...